Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), has setup its wholly owned subsidiary in Japan called Orchid Pharma Japan K K (Orchid Japan) which will drive Orchid’s foray into the high potential and growing Japanese generics market.

Orchid Chemicals & Pharmaceuticals Ltd. is a leading pharmaceutical company headquartered in Chennai, India involved in the development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals.

According to Orchid Japanese generics market is set to grow at a rapid pace in the coming years due to an increasing recognition in the government and healthcare sectors of the need for quality generic medicines. It is estimated that the generics market in Japan currently estimated at USD 2.5 billion could double itself to USD 5 billion in a short span of 5 years.

Orchid, with its comprehensive range of antibiotic and life style products plans to meet a broad spectrum of acute and chronic therapy needs of the growing Japanese healthcare market. The move into Japan follows Orchid’s highly successful emergence in the US antibiotics generics market as a leading cephalosporin generics player.

 Mr Kunihiko Iwata, President & Chief Executive Officer, Orchid Japan stated that Orchid Pharma Japan would endeavor to deliver cost-effective high quality drugs to the Japanese healthcare system, fully leveraging Orchid’s capabilities in a wide range of antibiotic and life style medicines.